{"id":"daratumumab-with-dexamethasone","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD38, daratumumab triggers the destruction of these cancer cells. This mechanism is thought to be responsible for the therapeutic effects of daratumumab in multiple myeloma. The addition of dexamethasone, a corticosteroid, is believed to enhance the efficacy of daratumumab by modulating the immune response and reducing inflammation.","oneSentence":"Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:19.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT06182774","phase":"PHASE3","title":"Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-04-10","conditions":"Multiple Myeloma","enrollment":570},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT06932562","phase":"PHASE3","title":"A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2025-12-23","conditions":"Multiple Myeloma","enrollment":1000},{"nctId":"NCT07452198","phase":"PHASE3","title":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2026-03-09","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT04933539","phase":"PHASE2","title":"Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-31","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT07095452","phase":"PHASE2, PHASE3","title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-01-08","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT05623020","phase":"PHASE3","title":"A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-11-10","conditions":"Multiple Myeloma","enrollment":1116},{"nctId":"NCT04973605","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2021-09-16","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":246},{"nctId":"NCT07222761","phase":"PHASE3","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-01-02","conditions":"Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":915},{"nctId":"NCT04910568","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-07-26","conditions":"Multiple Myeloma","enrollment":126},{"nctId":"NCT05083169","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-14","conditions":"Multiple Myeloma","enrollment":587},{"nctId":"NCT07477587","phase":"PHASE1","title":"A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-27","conditions":"Multiple Myeloma (MM)","enrollment":258},{"nctId":"NCT06615479","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-03-12","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":440},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT06353022","phase":"PHASE2","title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-06-26","conditions":"Multiple Myeloma","enrollment":103},{"nctId":"NCT01615029","phase":"PHASE1, PHASE2","title":"Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06-26","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT05438043","phase":"PHASE3","title":"A Study of Daratumumab","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-15","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT07149857","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT06142396","phase":"EARLY_PHASE1","title":"Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-11-01","conditions":"Multiple Myeloma, Renal Failure","enrollment":30},{"nctId":"NCT05552222","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-25","conditions":"Multiple Myeloma","enrollment":1590},{"nctId":"NCT07391657","phase":"PHASE3","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-23","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":508},{"nctId":"NCT05896228","phase":"PHASE2","title":"Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Benjamin T Diamond, MD","startDate":"2024-02-20","conditions":"Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":30},{"nctId":"NCT04151667","phase":"PHASE2","title":"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-22","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT06627309","phase":"","title":"Rapid dFLC Response Predict CHR in AL Amyloidosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10-26","conditions":"Systemic AL Amyloidosis","enrollment":50},{"nctId":"NCT06192979","phase":"NA","title":"Optimize First-line Treatment for AL Amyloidosis With t (11; 14)","status":"RECRUITING","sponsor":"Jin Lu, MD","startDate":"2024-01-05","conditions":"Amyloidosis; Systemic, AL Amyloidosis","enrollment":41},{"nctId":"NCT06083922","phase":"PHASE2","title":"A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-16","conditions":"Multiple Myeloma, Monoclonal Gammopathy of Renal Significance","enrollment":20},{"nctId":"NCT05434689","phase":"PHASE1, PHASE2","title":"COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-18","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT04656951","phase":"PHASE2","title":"Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT03937635","phase":"PHASE3","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-09-16","conditions":"Smoldering Plasma Cell Myeloma","enrollment":288},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT03589222","phase":"PHASE2","title":"SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2018-07-15","conditions":"Refractory Multiple Myeloma","enrollment":62},{"nctId":"NCT06953960","phase":"PHASE1, PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-23","conditions":"Multiple Myeloma","enrollment":130},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT07428369","phase":"PHASE2, PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":"Multiple Myeloma (MM)","enrollment":1570},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":21},{"nctId":"NCT06348147","phase":"PHASE2","title":"Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation","status":"SUSPENDED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-07","conditions":"Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation","enrollment":39},{"nctId":"NCT06892522","phase":"PHASE1, PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-30","conditions":"Multiple Myeloma","enrollment":440},{"nctId":"NCT05572515","phase":"PHASE3","title":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-29","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":614},{"nctId":"NCT04661137","phase":"PHASE2","title":"A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma","status":"SUSPENDED","sponsor":"Hackensack Meridian Health","startDate":"2021-03-16","conditions":"Multiple Myeloma","enrollment":96},{"nctId":"NCT03710603","phase":"PHASE3","title":"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2018-12-14","conditions":"Multiple Myeloma","enrollment":709},{"nctId":"NCT03275285","phase":"PHASE3","title":"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-10-25","conditions":"Plasma Cell Myeloma","enrollment":302},{"nctId":"NCT04113018","phase":"PHASE2","title":"Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-01-10","conditions":"Multiple Myeloma","enrollment":39},{"nctId":"NCT03652064","phase":"PHASE3","title":"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-06","conditions":"Multiple Myeloma","enrollment":395},{"nctId":"NCT05250973","phase":"PHASE2","title":"A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-03-01","conditions":"Amyloidosis","enrollment":151},{"nctId":"NCT05455320","phase":"PHASE3","title":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-13","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":864},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT07335887","phase":"PHASE2","title":"Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"AL Amyloidosis (AL), t(11;14) Positive","enrollment":39},{"nctId":"NCT05231629","phase":"PHASE2","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-12-13","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT06679101","phase":"PHASE3","title":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-12-16","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma","enrollment":520},{"nctId":"NCT05675319","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2023-03-03","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT04991103","phase":"PHASE2","title":"Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Multiple Myeloma, Amyloidosis","enrollment":40},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT05695508","phase":"PHASE2","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","status":"RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2022-12-01","conditions":"Multiple Myeloma","enrollment":160},{"nctId":"NCT04915248","phase":"PHASE2","title":"Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-07-11","conditions":"Plasmablastic Lymphoma","enrollment":28},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT01665794","phase":"PHASE1, PHASE2","title":"Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-08-13","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT05259839","phase":"PHASE1","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-10-20","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":283},{"nctId":"NCT03180736","phase":"PHASE3","title":"Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex","status":"COMPLETED","sponsor":"Stichting European Myeloma Network","startDate":"2017-06-14","conditions":"Multiple Myeloma","enrollment":304},{"nctId":"NCT04009109","phase":"PHASE2","title":"Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2020-10-21","conditions":"Myeloma, Multiple","enrollment":79},{"nctId":"NCT04068597","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","status":"RECRUITING","sponsor":"CellCentric Ltd.","startDate":"2019-08-09","conditions":"Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma","enrollment":250},{"nctId":"NCT07285239","phase":"PHASE3","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT04973137","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis","status":"TERMINATED","sponsor":"Prothena Biosciences Ltd.","startDate":"2021-08-30","conditions":"Light Chain (AL) Amyloidosis","enrollment":208},{"nctId":"NCT03290950","phase":"PHASE2","title":"A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-25","conditions":"Multiple Myeloma","enrollment":75},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT03201965","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-05","conditions":"Amyloidosis","enrollment":416},{"nctId":"NCT02970747","phase":"","title":"Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2016-10-25","conditions":"Multiple Myeloma in Relapse","enrollment":359},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT05392946","phase":"PHASE1, PHASE2","title":"Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-08-11","conditions":"Plasma Cell Myeloma","enrollment":49},{"nctId":"NCT03763162","phase":"PHASE2","title":"Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-17","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":40},{"nctId":"NCT01592370","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-08-02","conditions":"Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma","enrollment":320},{"nctId":"NCT02252172","phase":"PHASE3","title":"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-02-16","conditions":"Multiple Myeloma","enrollment":737},{"nctId":"NCT04176718","phase":"PHASE2","title":"Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM","status":"RECRUITING","sponsor":"Andrew Yee, MD","startDate":"2020-05-18","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse","enrollment":43},{"nctId":"NCT03500445","phase":"PHASE2","title":"Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-02-13","conditions":"Myeloma, Multiple Myeloma","enrollment":75},{"nctId":"NCT07018050","phase":"PHASE2","title":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-12","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":160},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":"AL Amyloidosis","enrollment":338},{"nctId":"NCT04045795","phase":"PHASE1","title":"Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Multiple Myeloma","enrollment":56},{"nctId":"NCT03993912","phase":"PHASE3","title":"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2019-10-17","conditions":"Multiple Myeloma","enrollment":294},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT01415882","phase":"PHASE2","title":"Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-31","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":165},{"nctId":"NCT02136134","phase":"PHASE3","title":"Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-08-15","conditions":"Multiple Myeloma","enrollment":498},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT07085728","phase":"PHASE2","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-08-11","conditions":"Myeloma Multiple","enrollment":74},{"nctId":"NCT06497738","phase":"","title":"A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-01","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT05835726","phase":"","title":"Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-01-01","conditions":"Multiple Myeloma, Daratumumab, Autologous Stem Cell Transplantation","enrollment":188},{"nctId":"NCT06952478","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-08-12","conditions":"Refractory or Relapsed Multiple Myeloma","enrollment":486},{"nctId":"NCT03314181","phase":"PHASE2","title":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-02","conditions":"Multiple Myeloma","enrollment":156},{"nctId":"NCT05308654","phase":"PHASE1","title":"A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-05-17","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":34},{"nctId":"NCT04643002","phase":"PHASE1, PHASE2","title":"Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-01-25","conditions":"Plasma Cell Myeloma Refractory","enrollment":258},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DaraD","Darzalex","Dara","Dex"],"phase":"phase_2","status":"active","brandName":"Daratumumab with dexamethasone","genericName":"Daratumumab with dexamethasone","companyName":"Hellenic Society of Hematology","companyId":"hellenic-society-of-hematology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells. Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}